<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238899</url>
  </required_header>
  <id_info>
    <org_study_id>HIT 2000 Interim Register</org_study_id>
    <nct_id>NCT02238899</nct_id>
  </id_info>
  <brief_title>Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma</brief_title>
  <official_title>Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Register is based on the study HIT 2000 that recruited patients until 31.12.2011. All
      german patients with intracranial medulloblastoma, CNS-PNET, ependymoma can be included in
      the register. Object of the register is to maintain the quality of diagnostic standard by
      using of central review (Neuroradiology, Pathology, and cranio spinal fluid (CSF) cytology).

      Furthermore, the register should enable to continue the collection of epidemiologic data and
      biological material (tumor material, CSF, and blood) for associated studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Register is based on the study HIT 2000 that recruited patients until 31.12.2011. All
      german patients with intracranial medulloblastoma, CNS-PNET, ependymoma can be included in
      the register. Object of the register is to maintain the quality of diagnostic standard by
      using of central review (Neuroradiology, Pathology, and cranio spinal fluid (CSF) cytology).

      Furthermore, the register should enable to continue the collection of epidemiologic data and
      biological material (tumor material, CSF, and blood) for associated studies.

      The register gives recommendations for the therapy of the patients, but these are not
      mandatory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>event free survival probability rates will be calculated</description>
  </primary_outcome>
  <enrollment type="Actual">354</enrollment>
  <condition>Medulloblastoma, Childhood</condition>
  <condition>Cerebral Primitive Neuroectodermal Tumor</condition>
  <condition>Ependymoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor material, CSF, and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with medulloblastoma, CNS-PNET (incl. pineoblastoma, ependymoblastoma,
        CNS-neuroblastoma), or ependymoma (WHO II/ III) and age at diagnosis 0-21 years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at diagnosis 0-21 years

          -  histologically proven medulloblastoma, CNS-PNET (incl. pineoblastoma,
             ependymoblastoma, CNS-neuroblastoma), or ependymoma (WHO II/ III)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Rutkowski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

